急诊雾化高渗盐水对急性毛细支气管炎住院率的影响:随机临床试验
GUERANDE 多中心双盲随机试验在法国 24 个儿科急诊纳入 777 例 6 周至 12 月龄、首次急性毛细支气管炎伴呼吸窘迫的婴儿,比较 3% 高渗盐水与 0.9% 生理盐水雾化。
要点
- 3% 高渗盐水雾化未显著降低急诊婴儿 24 小时内住院率。
- 高渗盐水组呼吸窘迫评分改善优于生理盐水组,但差异较小。
- 高渗盐水组轻度不良事件(如咳嗽加重)更常见,无严重不良事件。
核心结论
- 在儿科急诊首次发作的急性中重度毛细支气管炎婴儿中,与 0.9% 生理盐水相比,3% 高渗盐水雾化未显著降低 24 小时内住院率。
- 高渗盐水组呼吸窘迫评分改善更明显,但轻度不良事件更频繁,无严重不良事件。
研究设计与样本
- 评估 2445 例 6 周至 12 月龄婴儿,最终纳入 777 例首次急性毛细支气管炎伴呼吸窘迫且无慢性疾病的患儿。
- 干预为间隔 20 分钟的两次 20 分钟雾化,每次 4 mL 3% 高渗盐水或 4 mL 0.9% 生理盐水。
主要发现
- 777 例患儿中位年龄 3 个月(四分位距 2-5 个月),468 例(60.2%)为男性;385 例(49.5%)随机分至高渗盐水组,387 例(49.8%)分至生理盐水组,5 例未接受治疗。
- 24 小时内高渗盐水组 385 例中 185 例(48.1%)住院,生理盐水组 387 例中 202 例(52.2%)住院。
关键数值与推荐
- 主要结局为入组后 24 小时内住院率。
临床怎么用
- 对急诊首次发作的急性中重度毛细支气管炎婴儿,不应期待 3% 高渗盐水雾化显著降低住院率。
- 高渗盐水可能小幅改善呼吸窘迫评分,但需权衡咳嗽加重等轻度不良事件。
- 临床决策应结合患儿具体病情,不能仅凭雾化高渗盐水来减少留观或住院。
局限性
- 研究仅纳入首次发作、无慢性疾病的 6 周至 12 月龄婴儿,结论外推需谨慎。
- 主要结局为 24 小时内住院率,未报告更长期结局。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute bronchiolitis is the leading cause of hospitalization among infants. Previous studies, underpowered to examine hospital admission, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emergency department (ED). OBJECTIVE: To examine whether HS nebulization treatment would decrease the hospital admission rate among infants with a first episode of acute bronchiolitis. DESIGN, SETTING, AND PARTICIPANTS: The Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) study was a multicenter, double-blind randomized clinical trial on 2 parallel groups conducted during 2 bronchiolitis seasons (October through March) from October 15, 2012, through April 15, 2014, at 24 French pediatric EDs. Among the 2445 infants (6 weeks to 12 months of age) assessed for inclusion, 777 with a first episode of acute bronchiolitis with respiratory distress and no chronic medical condition were included. INTERVENTIONS: Two 20-minute nebulization treatments of 4 mL of HS, 3%, or 4 mL of normal saline (NS), 0.9%, given 20 minutes apart. MAIN OUTCOMES AND MEASURES: Hospital admission rate in the 24 hours after enrollment. RESULTS: Of the 777 infants included in the study (median age, 3 months; interquartile range, 2-5 months; 468 [60.2%] male), 385 (49.5%) were randomized to the HS group and 387 (49.8%) to the NS group (5 patients did not receive treatment). By 24 hours, 185 of 385 infants (48.1%) in the HS group were admitted compared with 202 of 387 infants (52.2%) in the NS group. The risk difference for hospitalizations was not significant according to the mixed-effects regression model (adjusted risk difference, -3.2%; 95% CI, -8.7% to 2.2%; P = .25). The mean (SD) Respiratory Distress Assessment Instrument score improvement was greater in the HS group (-3.1 [3.2]) than in the NS group (-2.4 [3.3]) (adjusted difference, -0.7; 95% CI, -1.2 to -0.2; P = .006) and similarly for the Respiratory Assessment Change Score. Mild adverse events, such as worsening of cough, occurred more frequently among children in the HS group (35 of 392 [8.9%]) than among those in the NS group (15 of 384 [3.9%]) (risk difference, 5.0%; 95% CI, 1.6%-8.4%; P = .005), with no serious adverse events. CONCLUSIONS AND RELEVANCE: Nebulized HS treatment did not significantly reduce the rate of hospital admissions among infants with a first episode of acute moderate to severe bronchiolitis who were admitted to the pediatric ED relative to NS, but mild adverse events were more frequent in the HS group. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01777347.
引用
- Angoulvant F, Bellêttre X, Milcent K, et al. Effect of Nebulized Hypertonic Saline Treatment in Emergency Departments on the Hospitalization Rate for Acute Bronchiolitis: A Randomized Clinical Trial. JAMA Pediatr. 2017. PMID: 28586918. doi:10.1001/jamapediatrics.2017.1333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。